AR065134A1 - Compuestos triciclicos, composicion que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por el receptor de glucocorticoides. - Google Patents

Compuestos triciclicos, composicion que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por el receptor de glucocorticoides.

Info

Publication number
AR065134A1
AR065134A1 ARP080100424A ARP080100424A AR065134A1 AR 065134 A1 AR065134 A1 AR 065134A1 AR P080100424 A ARP080100424 A AR P080100424A AR P080100424 A ARP080100424 A AR P080100424A AR 065134 A1 AR065134 A1 AR 065134A1
Authority
AR
Argentina
Prior art keywords
treatment
preparation
composition
glucocorticoid receptor
medicinal product
Prior art date
Application number
ARP080100424A
Other languages
English (en)
Spanish (es)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR065134A1 publication Critical patent/AR065134A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
ARP080100424A 2007-02-02 2008-02-01 Compuestos triciclicos, composicion que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por el receptor de glucocorticoides. AR065134A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88798107P 2007-02-02 2007-02-02

Publications (1)

Publication Number Publication Date
AR065134A1 true AR065134A1 (es) 2009-05-20

Family

ID=39315208

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP080100424A AR065134A1 (es) 2007-02-02 2008-02-01 Compuestos triciclicos, composicion que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por el receptor de glucocorticoides.
ARP080100425A AR065135A1 (es) 2007-02-02 2008-02-01 Compuestos triciclicos, composicion que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por el receptor de glucocorticoides.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP080100425A AR065135A1 (es) 2007-02-02 2008-02-01 Compuestos triciclicos, composicion que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por el receptor de glucocorticoides.

Country Status (42)

Country Link
US (7) US7598231B2 (cg-RX-API-DMAC7.html)
EP (1) EP2114970B1 (cg-RX-API-DMAC7.html)
JP (1) JP4599462B2 (cg-RX-API-DMAC7.html)
KR (2) KR101107949B1 (cg-RX-API-DMAC7.html)
CN (2) CN101616925B (cg-RX-API-DMAC7.html)
AP (1) AP2455A (cg-RX-API-DMAC7.html)
AR (2) AR065134A1 (cg-RX-API-DMAC7.html)
AT (1) ATE518872T1 (cg-RX-API-DMAC7.html)
AU (1) AU2008211613B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0808634A2 (cg-RX-API-DMAC7.html)
CA (1) CA2676670C (cg-RX-API-DMAC7.html)
CL (2) CL2008000329A1 (cg-RX-API-DMAC7.html)
CO (2) CO6220937A2 (cg-RX-API-DMAC7.html)
CR (2) CR10949A (cg-RX-API-DMAC7.html)
CU (2) CU23848B1 (cg-RX-API-DMAC7.html)
CY (2) CY1110962T1 (cg-RX-API-DMAC7.html)
DK (1) DK2114970T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2009000190A (cg-RX-API-DMAC7.html)
EA (1) EA016494B1 (cg-RX-API-DMAC7.html)
EC (2) ECSP099552A (cg-RX-API-DMAC7.html)
ES (2) ES2368286T3 (cg-RX-API-DMAC7.html)
GE (2) GEP20125404B (cg-RX-API-DMAC7.html)
GT (2) GT200900209A (cg-RX-API-DMAC7.html)
HN (2) HN2008000179A (cg-RX-API-DMAC7.html)
HR (1) HRP20110702T1 (cg-RX-API-DMAC7.html)
IL (1) IL199972A (cg-RX-API-DMAC7.html)
MA (2) MA31158B1 (cg-RX-API-DMAC7.html)
MX (1) MX2009008284A (cg-RX-API-DMAC7.html)
MY (3) MY153057A (cg-RX-API-DMAC7.html)
NI (2) NI200900148A (cg-RX-API-DMAC7.html)
NZ (1) NZ578638A (cg-RX-API-DMAC7.html)
PE (2) PE20081736A1 (cg-RX-API-DMAC7.html)
PL (1) PL2114970T3 (cg-RX-API-DMAC7.html)
PT (2) PT2114970E (cg-RX-API-DMAC7.html)
RS (2) RS51970B (cg-RX-API-DMAC7.html)
SI (1) SI2114970T1 (cg-RX-API-DMAC7.html)
SV (2) SV2009003346A (cg-RX-API-DMAC7.html)
TN (1) TN2009000324A1 (cg-RX-API-DMAC7.html)
TW (2) TWI347842B (cg-RX-API-DMAC7.html)
UA (2) UA94639C2 (cg-RX-API-DMAC7.html)
WO (1) WO2008093227A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA200906060B (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL126999A (en) 1996-07-24 2002-03-10 Warner Lambert Co Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain
PT2114970E (pt) 2007-02-02 2011-09-22 Pfizer Prod Inc Compostos tricíclicos e sua utilização como moduladores de receptor de glucocorticóide
KR101377860B1 (ko) * 2008-07-28 2014-03-25 화이자 인코포레이티드 페난트렌온 화합물, 조성물 및 방법
US8765787B2 (en) * 2008-11-21 2014-07-01 Bridge Pharma, Inc. Methods of treatment of xerophthalmia with self-preserving ocular formulations of norketotifen
US20100136097A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136094A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100137246A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100135983A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100136096A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100137843A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Delivery devices for modulating inflammation
US20100136095A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
AU2011251622A1 (en) 2010-05-10 2012-12-20 Radikal Therapeutics Inc. Lipoic acid and nitroxide derivatives and uses thereof
BR112013004322A2 (pt) * 2010-08-27 2016-06-21 Corcept Therapeutics Inc moduladores de azadecalin fundidos com piridil-aminas
UY33957A (es) * 2011-03-15 2012-10-31 Abbott Lab Moduladores de los receptores de hormonas nucleares
US8545904B1 (en) 2012-06-05 2013-10-01 Liquid Innovators, LLC Topical composition containing Carapa (andiroba) oil for psoriasis and other related dermatological disorders
US9227901B2 (en) 2012-07-05 2016-01-05 Abbvie Inc. Process for preparing bicyclic amine derivatives
TW201422590A (zh) 2012-09-07 2014-06-16 Abbvie Inc 雜環核激素受體調節劑
EP2935284A4 (en) 2012-12-21 2016-04-27 Abbvie Inc HETEROCYCLIC MODULATORS OF HORMONE NUCLEAR RECEPTORS
AU2015258904A1 (en) 2014-05-16 2016-11-17 Liqwd, Inc. Keratin treatment formulations and methods
KR102601505B1 (ko) * 2014-10-20 2023-11-14 오이스터 포인트 파마 인코포레이티드 안과 질환의 치료 방법
CN104591988A (zh) * 2014-12-29 2015-05-06 甘肃省化工研究院 6-溴-2-萘满酮的合成方法
CN113350353A (zh) * 2015-03-23 2021-09-07 墨尔本大学 呼吸性疾病的治疗
ES2893126T3 (es) 2016-04-07 2022-02-08 Oyster Point Pharma Inc Métodos de tratamiento de afecciones oculares
EP3877383A4 (en) 2018-11-07 2022-09-21 The University of Melbourne COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY DISEASES

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2576025B1 (fr) 1985-01-14 1987-01-23 Roussel Uclaf Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant
FR2600450B1 (fr) * 1986-06-19 1988-08-26 Pechiney Aluminium Procede de marquage individuel des anodes precuites pour la production electrolytique d'aluminium
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
IL122740A (en) 1997-01-15 2003-09-17 Akzo Nobel Nv 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
EE05584B1 (et) * 1999-04-30 2012-10-15 Pfizer Products Inc. Glkokortikoidretseptori modulaatorid
US6544781B1 (en) 1999-07-15 2003-04-08 The General Hospital Corporation Non-defective Epstein-Barr viral vector
IL146057A (en) * 2000-10-27 2007-09-20 Pfizer Prod Inc A process for the preparation of modulators of a non-steroidal glucocorticoid receptor
ES2262612T3 (es) * 2000-10-28 2006-12-01 Pfizer Products Inc. Moduladpres del receptor de glucocorticoides.
ES2246292T3 (es) * 2000-10-30 2006-02-16 Pfizer Products Inc. Moduladores de receptor glucocorticoide.
KR100793464B1 (ko) * 2000-11-20 2008-01-14 시게이트 테크놀로지 엘엘씨 Ｒｆｉｄ 태그 및 이를 디스크 드라이브에 부착하는 방법
MXPA03011935A (es) 2001-06-22 2004-03-26 Pfizer Prod Inc Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco.
MXPA04001893A (es) 2001-08-31 2005-03-07 Corcept Therapeutics Inc Metodos para inhibir deterioro cognoscitivo en adultos con sindrome de down.
EP1432684B1 (en) 2001-09-27 2009-03-25 Université de Liège Pyridinic sulfonamide derivatives, method of production and use thereof
DE10164366C1 (de) * 2001-12-28 2003-06-05 Rehau Ag & Co Permanentkathode
CA2474838C (en) 2002-02-01 2009-01-06 Pfizer Products Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
CN1665515A (zh) 2002-07-02 2005-09-07 科塞普特治疗公司 治疗与干扰素α治疗相关的精神病的方法
CA2491994C (en) * 2002-07-08 2013-11-05 Pfizer Products Inc. Modulators of the glucocorticoid receptor
EP1581234A4 (en) 2002-11-05 2007-09-12 Corcept Therapeutics Inc METHODS FOR TREATING MIGRAINE
CA2514966A1 (en) 2003-02-04 2004-08-19 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of postpartum psychosis
US8097606B2 (en) 2003-07-23 2012-01-17 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of catatonia
US20050080061A1 (en) 2003-07-23 2005-04-14 Corcept Therapeutics, Inc. Antiglucocorticoid therapy for the prevention of neurological damage in premature infants
TW200512181A (en) 2003-09-26 2005-04-01 Tanabe Seiyaku Co Amide-type carboxamide derivatives
ES2398239T3 (es) * 2003-11-10 2013-03-14 The Scripps Research Institute Composiciones y procedimientos para inducir la desdiferenciación celular
JP2007511501A (ja) * 2003-11-13 2007-05-10 ファイザー・プロダクツ・インク グルココルチコイド受容体調節剤として有用なオクタヒドロフェナンスレンヒドラジド誘導体
TWI370129B (en) 2005-02-14 2012-08-11 Msd Oss Bv Non steroidal glucocorticoid receptor modulators
WO2007131041A2 (en) 2006-05-02 2007-11-15 Corcept Therapeutics, Inc. The use of a glucocorticoid receptor ii antagonist to treat depression in patients taking il-2
PT2114970E (pt) 2007-02-02 2011-09-22 Pfizer Prod Inc Compostos tricíclicos e sua utilização como moduladores de receptor de glucocorticóide
BRPI0807121A2 (pt) * 2007-02-02 2014-04-08 Pfizer Prod Inc Compostos tricíclicos e seu uso como moduladores de receptor glicocorticóide

Also Published As

Publication number Publication date
ZA200906064B (en) 2010-05-26
CU23848B1 (es) 2012-10-15
PT2114888E (pt) 2011-01-04
NZ578638A (en) 2010-12-24
AU2008211613A1 (en) 2008-08-07
TWI373466B (en) 2012-10-01
ATE518872T1 (de) 2011-08-15
KR101107949B1 (ko) 2012-02-08
IL199972A (en) 2013-09-30
PE20090113A1 (es) 2009-02-13
ZA200906060B (en) 2010-05-26
CR10949A (es) 2009-08-07
CO6220937A2 (es) 2010-11-19
US20100286214A1 (en) 2010-11-11
CU23824A3 (es) 2011-10-31
ECSP099552A (es) 2009-08-28
EP2114970B1 (en) 2011-08-03
DOP2009000190A (es) 2009-08-31
SV2009003346A (es) 2010-04-13
TW200846325A (en) 2008-12-01
US20090281148A1 (en) 2009-11-12
IL199972A0 (en) 2010-04-15
CU20090132A7 (es) 2011-10-14
BRPI0808634A2 (pt) 2014-08-05
EA200970666A1 (ru) 2010-02-26
US20120088802A9 (en) 2012-04-12
UA95332C2 (uk) 2011-07-25
CA2676670C (en) 2012-03-13
CO6190603A2 (es) 2010-08-19
CY1111758T1 (el) 2015-10-07
MX2009008284A (es) 2009-08-12
US20080188443A1 (en) 2008-08-07
US7786097B2 (en) 2010-08-31
US20080312294A1 (en) 2008-12-18
WO2008093227A1 (en) 2008-08-07
MY146087A (en) 2012-06-29
US7598231B2 (en) 2009-10-06
US8445520B2 (en) 2013-05-21
HK1135108A1 (en) 2010-05-28
CA2676670A1 (en) 2008-08-07
NI200900149A (es) 2010-02-15
SI2114970T1 (sl) 2011-11-30
CN101616896A (zh) 2009-12-30
CN101616925A (zh) 2009-12-30
MY153057A (en) 2014-12-31
TN2009000324A1 (fr) 2010-12-31
CR10948A (es) 2009-08-07
GT200900209A (es) 2010-07-22
CU20090133A7 (es) 2011-10-31
JP4599462B2 (ja) 2010-12-15
CN101616896B (zh) 2012-07-04
PT2114970E (pt) 2011-09-22
GT200900210A (es) 2010-04-05
GEP20125404B (en) 2012-02-27
GEP20125426B (en) 2012-03-26
US20140142316A1 (en) 2014-05-22
UA94639C2 (ru) 2011-05-25
TW200838514A (en) 2008-10-01
US20140316139A1 (en) 2014-10-23
AR065135A1 (es) 2009-05-20
MY148780A (en) 2013-05-31
KR20090108115A (ko) 2009-10-14
ECSP099553A (es) 2009-08-28
RS51970B (sr) 2012-02-29
AU2008211613B2 (en) 2013-05-23
CY1110962T1 (el) 2015-06-11
SV2009003349A (es) 2010-04-13
US20120095062A1 (en) 2012-04-19
NI200900148A (es) 2010-02-15
TWI347842B (en) 2011-09-01
CL2008000329A1 (es) 2008-08-08
EP2114970A1 (en) 2009-11-11
KR20090107080A (ko) 2009-10-12
CN101616925B (zh) 2012-05-23
US7547714B2 (en) 2009-06-16
PL2114970T3 (pl) 2011-11-30
MA31158B1 (fr) 2010-02-01
RS51646B (sr) 2011-10-31
AP2009004942A0 (en) 2009-08-31
HRP20110702T1 (hr) 2011-10-31
KR101114682B1 (ko) 2012-03-14
EA016494B1 (ru) 2012-05-30
AP2455A (en) 2012-08-31
MA31117B1 (fr) 2010-01-04
ES2368286T3 (es) 2011-11-16
HN2008000178A (es) 2011-02-25
ES2353822T3 (es) 2011-03-07
US8901310B2 (en) 2014-12-02
DK2114970T3 (da) 2011-09-19
JP2010517990A (ja) 2010-05-27
HN2008000179A (es) 2010-06-09
CL2008000330A1 (es) 2008-08-08
PE20081736A1 (es) 2008-11-28
US8158660B2 (en) 2012-04-17

Similar Documents

Publication Publication Date Title
AR065134A1 (es) Compuestos triciclicos, composicion que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por el receptor de glucocorticoides.
CR20120591A (es) Derivados de aminopirimidina como moduladores de la lrrk2
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
UY33921A (es) Oxazinopteridinas y oxazinoptiridinonas n-sustituidas
ECSP088329A (es) Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8
UY33890A (es) Nuevas azaindolilfenil sulfonamidas como inhibidores de serina/ treonina cinasa
UY31314A1 (es) Amidas heterociclicas y sus métodos de uso-976
UY30314A1 (es) Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmacéuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
UY32611A (es) Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750
CO6321136A2 (es) Derivados de indazol sustituido por axadiazol para uso como agonistas de esfingosina 1 fosfato (s1p)
UY31198A1 (es) Amidas de ácidos benzoicos triazinil sustituidos, composiciones farmacéticas conteniéndolos y aplicaciones.
ECSP088763A (es) Nuevas combinaciones terapéuticas para el tratamiento de la depresión
ECSP14013215A (es) Compuestos novedosos
UY31922A (es) Compuestos
CO6382089A2 (es) Compuestos,composiciones y metodos para el tratamiento de enfermadades causadas por un b-amiloide y sinucleinopatias
UY33655A (es) Co-cristales y sales de inhibidores de ccr30
ECSP11010956A (es) Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos
DOP2017000107A (es) Diamino-quinoleina 2,4 sustituida como nuevos agentes anticancerigenos
MX2021004566A (es) Compuestos terapeuticos.
ECSP099425A (es) Derivados de amina y su uso en enfermedades mediadas por el adrenorecetor beta 2
ECSP11011108A (es) Piperidina espiro pirrolidinona y piperidinona sustituidas, su preparación y su uso terapéutico
UY29735A1 (es) Piperazinas sustituidas como antagonistas de receptores de glutamato metabotrópicos
ECSP088250A (es) Derivados de pirazol como agentes terapéuticos
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
MX343517B (es) 2,4 pirimidinadiaminas sustituidas para su uso en lupus discoide.

Legal Events

Date Code Title Description
FG Grant, registration